Generex Biotechnology Corp (GNBT) SEC Filing 8-K Material Event for the period ending Friday, October 26, 2018

Generex Biotechnology Corp

CIK: 1059784 Ticker: GNBT

View differences made from one to another to evaluate Generex Biotechnology Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Generex Biotechnology Corp.


Assess how Generex Biotechnology Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Generex Biotechnology Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Generex Biotechnology Corp provided additional information to their SEC Filing as exhibits

Ticker: GNBT
CIK: 1059784
Form Type: 8-K Corporate News
Accession Number: 0001607062-18-000363
Submitted to the SEC: Fri Oct 26 2018 4:08:44 PM EST
Accepted by the SEC: Fri Oct 26 2018
Period: Friday, October 26, 2018
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: